Prescribing information

 

Prescribing information

   

Welcome to the Kisqali on-demand video page. Below you can access the latest educational videos organised and sponsored by Novartis and hosted by experts in the field of advanced breast cancer.

You will be required to register/log in to watch the videos.

 

Management of premenopausal (HR+/HER2-) Advanced breast cancer patients with Kisqali thumbnail

MANAGEMENT OF PREMENOPAUSAL (HR+/HER2–) ADVANCED BREAST CANCER PATIENTS ON KISQALI + ET*

In this series, Drs Caroline Archer, Richard Simcock and Mark Tuthill discuss the latest international consensus guidelines for advanced breast cancer, as well as randomised and open-label phase III studies with KISQALI.

Video from a webinar event on 25th February 2021

Watch

 

*KISQALI is not recommended to be used in combination with Tamoxifen.1

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

 

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | July 2021 | 138489
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]